# ResMed (RMD) Q4 FY2026 earnings

Results filed 2026-08-06 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/rmd/2026-q4/
Press release and documents: https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/0001193125-26-337962-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

ResMed completed its Noctrix Health acquisition for restless legs wearables, agreed to sell MatrixCare, and partnered with ŌURA while launching AirSense 11 in Taiwan.

ResMed ended fiscal 2026 with demand strong across sleep devices, masks, accessories and software. Americas and Rest of World sleep businesses both grew, while Residential Care Software grew only modestly. It completed the Noctrix Health acquisition, which adds an FDA De Novo classified wearable therapy for Restless Leg Syndrome, and partnered with ŌURA on sleep health education and pathways to care.
Management says it will use its global scale and enhance its digital capabilities to improve patient outcomes and reduce healthcare costs. The portfolio is being narrowed: the MatrixCare business is being sold, with closing expected in the first quarter of fiscal 2027. The main risk is execution: integrating a new device category while a $42 million Astral field safety notification shows quality issues can carry costs.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Q4 revenue | $1,464 | up 9% from a year ago | GAAP |
| Q4 net income | $383 | up 1% from a year ago | GAAP |
| Q4 diluted EPS | $2.64 | up 2% from a year ago | GAAP |
| Q4 non-GAAP diluted EPS | $2.95 | up 16% from a year ago | non-GAAP |
| Q4 gross margin | 58.8% | down 200 bps from a year ago | GAAP |
| Q4 non-GAAP gross margin | 62.3% | up 90 bps from a year ago | non-GAAP |
| Q4 income from operations | $449 | down 1% from a year ago | GAAP |
| Q4 operating margin | 30.7% | down 300 bps from a year ago | GAAP |
| Q4 operating cash flow | $455 | down 16% from a year ago |  |
| Q4 free cash flow | $404 | down 21% from a year ago |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Americas Sleep and Breathing Health | $853 | up 8% |
| Rest of World Sleep and Breathing Health | $439 | up 13%, up 10% in constant currency |
| Total devices | $750 | up 8%, up 7% in constant currency |
| Masks and other | $542 | up 11%, up 10% in constant currency |
| Residential Care Software | $172 | up 3%, up 2% in constant currency |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Capital to be returned to shareholders | fiscal year 2027 | more than $1.85 billion |

## Key takeaways

1. **Noctrix deal extends ResMed beyond sleep apnea** ResMed completed the acquisition of Noctrix Health, which sells FDA De Novo classified wearable therapeutics for Restless Leg Syndrome. This adds a new condition and device category to its home-care portfolio.
2. **MatrixCare sale narrows the software portfolio** ResMed agreed to sell its MatrixCare business, with closing expected in the first quarter of fiscal 2027. Residential Care Software grew only 2% in constant currency, so the sale points to a sharper focus on sleep and breathing health.
3. **ŌURA partnership targets sleep care pathways** ResMed partnered with ŌURA to expand access to sleep health education and pathways to care. It is a consumer-facing route to bring more people into diagnosis and treatment.
4. **Masks and accessories outgrew devices** Masks and other grew 10% in constant currency against 7% for devices. Demand was described as strong across devices, masks, accessories and software.
5. **Astral safety notification shows a quality cost** ResMed booked $42 million of Astral field safety notification expenses, which is the main reason GAAP gross margin of 58.8% trailed non-GAAP gross margin of 62.3%. It shows product-quality events can affect profitability even as productivity gains continue.

## Questions

**What did ResMed do to expand its product portfolio this quarter?** It completed the acquisition of Noctrix Health, which sells FDA De Novo classified wearable therapeutics for Restless Leg Syndrome. It also launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.
**What is happening to ResMed's MatrixCare business?** ResMed agreed to sell MatrixCare, with the transaction expected to close in the first quarter of its fiscal year 2027.
**Where is ResMed expanding AirSense 11?** It launched AirSense 11 in Taiwan, following other launches in APAC, EMEA and the Americas.
**Why did ResMed partner with ŌURA?** The partnership aims to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.
**Which parts of the business grew fastest in the quarter?** In constant currency, Rest of World Sleep and Breathing Health grew 10% and masks and other grew 10%, while Residential Care Software grew 2%.

## Slides and investor documents

- [Q4 FY26 Company Overview](https://investor.resmed.com/_assets/_5bcd8acc7e1b5c73a62283d752dd0b96/resmed/db/2579/48776/pdf/Resmed+Q4+FY26+Company+Overview.pdf) (Document)

